More News
HEALTHCARE | Staff Reporter, Singapore
view(s)

Aslan Pharmaceuticals reveals net loss in third quarter

The net loss is still reported despite lessening of expenses.

Aslan Pharmaceuticals reported a net loss of $3.5m for the third quarter of 2020 but still less than last year’s $5.2m net loss in the same time period.

Cash expenditure for operations for Q3 was $2.6m, less than the $7m in the same period in 2019.

The company also reported that expenses for research and development were less in Q3 compared to last year because of the completion of clinical studies related to varlitinib.
 

Do you know more about this story? Contact us anonymously through this link.

Click here to learn about advertising, content sponsorship, events & rountables, custom media solutions, whitepaper writing, sales leads or eDM opportunities with us.

To get a media kit and information on advertising or sponsoring click here.